Condition: Unspecified Adult Solid Tumor, Protocol Specific · Sponsor: Maastricht University Medical Center
A modular, first time in human, open label, multiple dose, accelerated escalation with cohort expansion study of the safety and pharmacokinetics of intravenous infusion of CP-506, a tumor agnostic Hypoxia Activated Prodrug in patients with HRD/FAD solid tumours or tumor types with high incidence of HRD/FAD in monotherapy or in combination with carboplatin or patients with solid tumour and oligoprogressive disease receiving immune checkpoint inhibitors (ICI): a phase I-IIa clinical trial
This description comes directly from the study's public registry record.
Ludwig Dubois, PhD · +31433882909 · ludwig.dubois@maastrichtuniversity.nl
Always discuss trial participation with your own doctor first.
| Institut Jules Bordet | Brussels, Belgium | Not Yet Recruiting |
| UZ Gent | Ghent, Belgium | Not Yet Recruiting |
| Academisch Ziekenhuis Maastricht (Leading Centre) | Maastricht, Limburg, Netherlands | Recruiting |
| Erasmus MC | Rotterdam, Netherlands | Recruiting |
| Institut Vall d'Hebron | Barcelona, Spain | Not Yet Recruiting |
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT04954599